Completed PHASE2 INTERVENTIONAL 2-arm NCT00973128

Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis (GMCSFSbv)

Reduced Doses of Antimony Plus Recombinant Human GM-CSF Compared With Antimony in Standard Doses for Cutaneous Leishmaniasis: a Randomized, Single-blind, Placebo-controlled, Pilot Study

Sponsor: Fundação de Amparo à Pesquisa do Estado da Bahia

Conditions Cutaneous Leishmaniasis

Interventions GMCSF plus Antimony reduced dose Meglumine antimoniate

Updated 4 times since 2017 Last updated: Sep 8, 2009 Started: Feb 29, 2004 Primary completion: Oct 31, 2006 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cutaneous Leishmaniasis and is currently completed. Fundação de Amparo à Pesquisa do Estado da Bahia leads this study, which shows 4 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundação de Amparo à Pesquisa do Estado da Bahia
Hospital Universitário Professor Edgard Santos

Data source: Hospital Universitário Professor Edgard Santos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Valença, Brazil